Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,265 | -10,256 | -7,707 | -5,068 | -1,967 |
| Depreciation Amortization | 87 | 139 | 58 | 8 | 5 |
| Other Working Capital | -373 | -679 | -1,154 | 4 | -233 |
| Other Operating Activity | 417 | 3,534 | 2,834 | 1,184 | 523 |
| Operating Cash Flow | $-2,134 | $-7,262 | $-5,968 | $-3,873 | $-1,671 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -239 | -10 | -8 | -2 |
| Investing Cash Flow | $N/A | $-239 | $-10 | $-8 | $-2 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -32 | -184 | -141 | -106 | -71 |
| Common Stock Issued | 873 | 9,900 | 9,785 | 9,537 | 9,537 |
| Other Financing Activity | 0 | 278 | 278 | 278 | 278 |
| Financing Cash Flow | $841 | $9,994 | $9,922 | $9,709 | $9,744 |
| Beginning Cash Position | 2,921 | 429 | 429 | 429 | 429 |
| End Cash Position | 1,628 | 2,921 | 4,372 | 6,257 | 8,500 |
| Net Cash Flow | $-1,293 | $2,493 | $3,944 | $5,829 | $8,071 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,134 | -7,262 | -5,968 | -3,873 | -1,671 |
| Capital Expenditure | N/A | -239 | -10 | -8 | -2 |
| Free Cash Flow | -2,134 | -7,501 | -5,978 | -3,881 | -1,673 |